<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41858">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02561455</url>
  </required_header>
  <id_info>
    <org_study_id>2215-CL-0109</org_study_id>
    <nct_id>NCT02561455</nct_id>
  </id_info>
  <brief_title>Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial</brief_title>
  <official_title>A Phase 1/2 Open-label Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to provide access to continued treatment for subjects who
      participated in other Astellas sponsored ASP2215 trials and for whom the Investigator feels
      the subject may benefit from continued treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessed by Adverse Events (AEs)</measure>
    <time_frame>Until End of Treatment (up to 2 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by safety laboratory evaluations</measure>
    <time_frame>Until End of Treatment (up to 2 years)</time_frame>
    <description>Safety laboratory tests include chemistry, hematology, serum pregnancy, coagulation and urinalysis</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>ASP2215</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will continue dosing at the dose received in original study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP2215</intervention_name>
    <description>oral</description>
    <arm_group_label>ASP2215</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must currently be participating in an Astellas sponsored, single agent
             ASP2215 trial, receiving ASP2215 and can enroll into this rollover study without
             interruption of study drug, or with no more than 2 weeks interruption in study drug.

          -  Subject must be deriving benefit from continued treatment as determined by the
             Investigator.

          -  Female subject must either:

               -  Be of non-childbearing potential: post-menopausal (defined as at least 1 year
                  without any menses) prior to Screening, or documented surgically sterile (at
                  least 1 month prior to Screening)

               -  Or, if of childbearing potential, Agree not to try to become pregnant during the
                  study and for 45 days after the final study drug administration; And have a
                  negative urine pregnancy test at Day 1; And, if heterosexually active, agree to
                  consistently use two forms of highly effective birth control (at least one of
                  which must be a barrier method) starting at Screening and throughout the study
                  period and for 45 days after the final study drug administration.

          -  Female subject must agree not to breastfeed starting at Screening and throughout the
             study period, and for 45 days after the final study drug administration.

          -  Female subject must not donate ova starting at Screening and throughout the study
             period, and for 45 days after the final study drug administration.

          -  Male subject and their female spouse/partners who are of childbearing potential must
             be using highly effective contraception consisting of two forms of birth control (at
             least one of which must be a barrier method) starting at Screening and continue
             throughout the study period, and for 105 days after the final study drug
             administration.

          -  Male subject must not donate sperm starting at Screening and throughout the study
             period and, for 105 days after the final study drug administration.

          -  Subject agrees not to participate in another interventional study while on treatment.

        Exclusion Criteria:

          -  Subject requires treatment with concomitant drugs that are strong inducers of
             cytochrome P450 (CYP)3A4 or strong inhibitors or inducers of P-glycoprotein (P-gp) or
             substrates of multidrug and toxin extrusion protein 1 (MATE1) with the exception of
             drugs that are considered absolutely essential for the care of the subject.

          -  Subject requires treatment with concomitant drugs that target serotonin
             5-hydroxytryptamine receptor 1 (5HT1R) or 5-hydroxytryptamine receptor 2B (5HT2BR) or
             sigma nonspecific receptor with the exception of drugs that are considered absolutely
             essential for the care of the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Executive Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Astellas Pharma Global Development</last_name>
    <phone>800-888-7704</phone>
    <phone_ext>5473</phone_ext>
    <email>Astellas.registration@astellas.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site US10001</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 30, 2017</lastchanged_date>
  <firstreceived_date>September 25, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced solid tumors</keyword>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>ASP2215</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
